Reference

High-performance thin-layer chromatographic determination of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in urine and comparison with high-performance liquid chromatography

High-performance thin-layer chromatographic determination of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in urine and comparison with high-performance liquid chromatography.Some chemicals with cas registry numbers like 69389-97-5 and 82801-81-8 are also used. Pisternick, Wendelgard; Kovar, Karl-Artur; Ensslin, Hartmut ( Pharmaceutical Institute, University of Tuebingen, Auf der Morgenstelle 8, Tubingen 72076, Germany). Journal of Chromatography, B: Biomedical Applications, 688(1), 63-69 (English) 1997 Elsevier. CODEN: JCBBEP. ISSN: 0378-4347. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The consumption of N-ethyl-3,4-methylenedioxyamphetamine (MDE, 1), an analog of ecstasy, can be detected by direct in situ HPTLC-FTIR measurement of the main metabolite N-ethyl-4-hydroxy-3-methoxyamphetamine (HME, 2). HME (2) can, like the other important metabolite 3,4-methylenedioxyamphetamine (MDA, 3) and unchanged MDE (1), be detd. quant. in urine by HPTLC-UV after two-step automatic development. The results have been compared with those obtained using an HPLC method. The differences were not generally significant. Small deviations were attributable to the different sample prepn. methods necessary. The working range for the HPTLC method was between 0.1 and 8.2 mg/mL and for the HPLC method between 0.2 and 60.0 mg/mL. The method std. deviations were 2.66-4.91 (HPTLC) and 0.48-3.67 (HPLC). .

A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives

A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Stone, Donna M.; Johnson, Michel; Hanson, Glen R.; Gibb, James W. (Dep. Biochem. Pharmacol. Toxicol., Univ. Utah, Salt Lake City, UT 84112, USA). Eur. J. Pharmacol., 134(2), 245-8 (English) 1987. CODEN: EJPHAZ. ISSN: 0014-2999. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Three psychoactive amphetamine congeners were evaluated for their ability to cause long-term changes in several neurochem. parameters indicative of central serotonergic function. Two weeks after multiple doses (10 mg/kg) of 3,4-methylenedioxyamphetamine (MDA) [4764-17-4] or its N-methylated deriv., 3,4-methylenedioxymethamphetamine [42542-10-9], selective and dramatic decreases were obsd. in regional brain tryptophan hydroxylase (TPH) [9037-21-2] activities and in corresponding concns. of 5-hydroxytryptamine [50-67-9] and its primary metabolite, 5-hydroxyindoleacetic acid [54-16-0]. However, the N-ethylated deriv. of MDA, N-ethyl-3,4-methylenedioxyamphetamine [82801-81-8], was much less potent in its ability to lower brain hydroxyindoles, and in most regions examd. it did not significantly affect TPH activity. 300-62-9 and 82801-81-8 are just another two chemicals used in this study. The neurotoxic implications of these results are discussed. .